Lushang Freda PharmaceuticalLtd Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | n/a |
| Management average tenure | 1.2yrs |
| Board average tenure | 3.4yrs |
Recent management updates
Recent updates
Many Still Looking Away From Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223)
Dec 12
Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) Doing What It Can To Lift Shares
Jun 21Is Now An Opportune Moment To Examine Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223)?
Apr 16Lushang Freda PharmaceuticalLtd's (SHSE:600223) Solid Earnings May Rest On Weak Foundations
Mar 28Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Mar 04A Look At The Fair Value Of Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223)
Feb 27CEO
Lushang Freda PharmaceuticalLtd has no CEO, or we have no data on them.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Financial Director | 1.2yrs | no data | no data | |
| Accounting Supervisor | no data | no data | no data | |
| Deputy GM & Secretary | 1.2yrs | no data | no data | |
| Deputy General Manager | 1.2yrs | no data | no data | |
| Deputy General Manager | 1.2yrs | no data | no data | |
| Deputy General Manager | 1.2yrs | no data | no data |
1.2yrs
Average Tenure
46.5yo
Average Age
Experienced Management: 600223's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Director | 3.4yrs | CN¥100.00k | no data | |
| Independent Director | 3.4yrs | CN¥100.00k | no data | |
| Chairman of the Supervisory Board | 4.9yrs | no data | no data | |
| Director | less than a year | no data | no data |
3.4yrs
Average Tenure
55yo
Average Age
Experienced Board: 600223's board of directors are considered experienced (3.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 21:56 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Lushang Freda Pharmaceutical Co.,Ltd. is covered by 21 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhi Xue Diao | Avic Securities Co., Ltd |
| Tian Shixin | BOCI Research Ltd. |
| Zhuonan Xu | China International Capital Corporation Limited |